[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY34786A - Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo - Google Patents

Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo

Info

Publication number
UY34786A
UY34786A UY0001034786A UY34786A UY34786A UY 34786 A UY34786 A UY 34786A UY 0001034786 A UY0001034786 A UY 0001034786A UY 34786 A UY34786 A UY 34786A UY 34786 A UY34786 A UY 34786A
Authority
UY
Uruguay
Prior art keywords
nifedipino
cilexetilo
candesartan
procedure
manufacture
Prior art date
Application number
UY0001034786A
Other languages
English (en)
Inventor
Funke Dr Adrian
Meyer Guenter
Smikalla Dr Martina
Meeners Andreas
Wirges Markus
Brock Daniela
Just Sarah
Kleinebudde Prof Dr Peter
Knop Dr Klaus
Zeitler Dr Jochen Axel
Boeggering Rolf-Anton
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34786(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY34786A publication Critical patent/UY34786A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a procedimientos de fabricación para la preparación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo y opcionalmente al menos un diurético caracterizada porque el nifedipino se libera en el cuerpo de una manera controlada (modificada) y el candesartan cilexetilo se libera rápidamente (liberación inmediata (LI)) y opcionalmente el diurético se libera rápidamente (liberación inmediata (LI )) y a las formas farmacéuticas que pueden obtenerse mediante estos procedimientos
UY0001034786A 2012-05-07 2013-05-06 Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo UY34786A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167035 2012-05-07
EP13151946 2013-01-18

Publications (1)

Publication Number Publication Date
UY34786A true UY34786A (es) 2013-11-29

Family

ID=48289160

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034786A UY34786A (es) 2012-05-07 2013-05-06 Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo

Country Status (27)

Country Link
US (1) US9539176B2 (es)
EP (1) EP2846777B1 (es)
JP (1) JP6231553B2 (es)
KR (1) KR20150007297A (es)
CN (1) CN104507459A (es)
AR (1) AR090940A1 (es)
AU (1) AU2013258273A1 (es)
BR (1) BR112014027618A2 (es)
CA (1) CA2872542A1 (es)
CL (1) CL2014002988A1 (es)
CO (1) CO7190241A2 (es)
CR (1) CR20140511A (es)
DO (1) DOP2014000251A (es)
EA (1) EA201492026A1 (es)
EC (1) ECSP14025965A (es)
ES (1) ES2612532T3 (es)
GT (1) GT201400245A (es)
HK (1) HK1204292A1 (es)
IL (1) IL235040A0 (es)
IN (1) IN2014DN09045A (es)
MX (1) MX2014013320A (es)
PE (1) PE20142284A1 (es)
PH (1) PH12014502469A1 (es)
SG (1) SG11201406363VA (es)
TW (1) TW201410266A (es)
UY (1) UY34786A (es)
WO (1) WO2013167453A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9244004B2 (en) * 2013-08-08 2016-01-26 Stichting Sron—Netherlands Institute For Space Research Method and system for inspection of composite assemblies using terahertz radiation
US10071482B2 (en) 2015-08-19 2018-09-11 Ford Global Technologies, Llc Robotic vehicle painting instrument including a terahertz radiation device
US10365229B2 (en) * 2015-12-31 2019-07-30 Kaiser Optical Systems, Inc. Real-time characterization of pharmaceutical tablet coatings using Raman spectroscopy
DE102016222667A1 (de) * 2016-11-17 2018-05-17 Robert Bosch Gmbh Verfahren zum Betrieb einer Anlage zum Herstellen von pharmazeutischen Produkten
US10323932B1 (en) 2017-12-28 2019-06-18 Ford Motor Company System for inspecting vehicle bodies
JP7263047B2 (ja) * 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
CN110411978B (zh) * 2019-07-26 2020-05-22 中国农业大学 一种物料均匀性检测设备及检测方法
JP7312676B2 (ja) 2019-11-13 2023-07-21 ナブテスコ株式会社 ブレーキ異常判定装置、ブレーキ状態記憶装置、異常判定方法、異常判定プログラム、及びブレーキ制御装置
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4426019A (en) 1981-10-15 1984-01-17 The Coca-Cola Company Membrane seal and knife combination for a post-mix beverage dispensing system
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
EP0386440B1 (de) 1989-02-11 1992-08-05 Bayer Ag Arzneimittel mit kontrollierter Wirkstoffabgabe
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
EP0565634B1 (en) 1990-12-14 1999-03-17 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
US5656650A (en) 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
EP1191924A4 (en) 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL PHARMACEUTICAL FORM FOR PULSED ADMINISTRATION OF (D-THREO) METHYLPHENIDATE AND ANOTHER CNS STIMULATING SUBSTANCE
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
EP1413315A4 (en) 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
WO2003080057A1 (fr) 2002-03-27 2003-10-02 Bayer Aktiengesellschaft Comprime-noyau de taille reduite contenant de la nifedipine
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
WO2005009412A1 (en) 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005079751A2 (en) 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
WO2006122254A2 (en) 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Stable micronized candesartan cilexetil and methods for preparing thereof
DE102005031577A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
WO2008003560A1 (en) 2006-07-03 2008-01-10 Novo Nordisk A/S Coupling for injection devices
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008065097A2 (en) 2006-11-28 2008-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
CA2703365A1 (en) 2007-10-25 2009-04-30 Yuka Yamanouchi Nifedipine-containing press coated tablet and method of preparing the same
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
MX2013002146A (es) 2010-09-03 2013-04-03 Astrazeneca Uk Ltd Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.

Also Published As

Publication number Publication date
TW201410266A (zh) 2014-03-16
KR20150007297A (ko) 2015-01-20
BR112014027618A2 (pt) 2017-06-27
CL2014002988A1 (es) 2015-03-13
SG11201406363VA (en) 2014-11-27
IL235040A0 (en) 2014-12-31
MX2014013320A (es) 2015-08-10
DOP2014000251A (es) 2014-12-31
CR20140511A (es) 2014-12-02
EP2846777A1 (en) 2015-03-18
WO2013167453A1 (en) 2013-11-14
GT201400245A (es) 2015-08-25
EP2846777B1 (en) 2016-10-26
IN2014DN09045A (es) 2015-05-22
ES2612532T3 (es) 2017-05-17
HK1204292A1 (en) 2015-11-13
ECSP14025965A (es) 2015-12-31
US9539176B2 (en) 2017-01-10
CO7190241A2 (es) 2015-02-19
EA201492026A1 (ru) 2015-09-30
PH12014502469A1 (en) 2014-12-22
JP6231553B2 (ja) 2017-11-15
PE20142284A1 (es) 2014-12-17
AU2013258273A1 (en) 2014-11-13
CN104507459A (zh) 2015-04-08
JP2015515999A (ja) 2015-06-04
US20130309302A1 (en) 2013-11-21
CA2872542A1 (en) 2013-11-14
AR090940A1 (es) 2014-12-17

Similar Documents

Publication Publication Date Title
NO2021012I1 (no) avapritinib and pharmaceutically acceptable salts thereof
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
FR21C1059I2 (fr) Compositions pharmaceutiques
CL2015000450A1 (es) Métodos y composiciones para el tratamiento de una afección genética
DK2709667T3 (da) Bio-orthogonal lægemiddelaktivering
UY34651A (es) ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?..
NI201600071A (es) Compuestos de inhibidor de autotaxina
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CR20130354S (es) Banda de rodadura de neumático
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
EP3030323A4 (en) Kdm1a inhibitors for the treatment of disease
UY34607A (es) Plantas resistentes al glifosato y métodos asociados.
UY34885A (es) Proteínas de unión anti-mesotelina
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
BR112016004110A2 (pt) Embalagens invioláveis e métodos para a fabricação das mesmas
BR112016013333A2 (pt) composição para cuidado oral
BR112013028512A2 (pt) cápsula
BR112015021003A2 (pt) composições e métodos para a produção biológica de isopreno.
DK3019166T3 (da) A Pharmaceutical Combination for the Treatment of Melanoma
UY34385A (es) Ésteres lábiles de agroquímicos para una liberación controlada y reducción del desplazamiento fuera del sitio de acción
UY34902A (es) Forma cristalina de un derivado de indolinona y su uso
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CO7200262A2 (es) Nueva dosificación y formulación

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210526